PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma. - Buckley, Hannah L.; Collinson, Fiona J.; Ainsworth, Gemma; Poad, Heather; Flanagan, Louise; Katona, Eszter; Howard, Helen C.; Murden, Geraldine; Banks, Rosamonde E.; Brown, Joanne; Velikova, Galina; Waddell, Tom; et al. (BMC Cancer, 2019)